HW
AKBA icon

Hancock Whitney’s Akebia Therapeutics AKBA Stock Holding History

Hancock Whitney’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-66,900
Closed -$995K – 553
2017
Q4 		$995K Buy
+66,900
New +$1.11M 0.04% 348

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Hancock Whitney's AKBA Position: Q1 2018 in Review

Hancock Whitney sold out of Akebia Therapeutics (AKBA) in Q1 2018, closing a stake of 66,900 shares — an estimated $995K sold.

Hancock Whitney first reported a position in AKBA in Q4 2017 and held it in 1 quarter. The position peaked at $995K in Q4 2017. 153 funds tracked by Wall St. Rank hold AKBA as of Q1 2018.

  • Hancock Whitney reported no remaining Akebia Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Hancock Whitney sold 66,900 Akebia Therapeutics shares in Q1 2018, an estimated $995K.
  • Hancock Whitney first reported a position in Akebia Therapeutics in Q4 2017 and held it in 1 quarter.
  • Hancock Whitney's Akebia Therapeutics position peaked at $995K in Q4 2017.
  • 153 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2018.

Based on Hancock Whitney's 13F filing for Q1 2018, filed 15 May 2018.